FDA-AACR Workshop to Address Multiple Myeloma Clinical Trial Disparities
Thanks to a wave of newly approved therapies in the past two decades, survival rates for multiple myeloma have increased dramatically. Still, the cancer research community is concerned about disparities in patient care. African Americans are disproportionately affected by multiple myeloma, having a two- to three-fold higher incidence of multiple myeloma compared with whites and representing 20 percent of the multiple myeloma patients in the U.S. Despite this difference in incidence, African Americans have historically been underrepresented in clinical trials for multiple myeloma therapies.
